Please Wait...

CXCL10 // C-X-C motif chemokine 10

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

CXCL10 is a 10 kDa protein and is also known as Interferon γ-induced protein 10 (IP-10) or small-inducible cytokine B10. This cytokine is implicated in the cell migration of leukocytes and its expression is dependent on interferon γ (IFN γ) in numerous cell types (neutrophils, monocytes, T lymphocytes, endothelial cells, fibroblast, keratinocytes, and thyrocytes among others)(Antonelli et al., 2014).

The CXCR3 receptor also binds the IFN γ inducible chemokines CXCL9 and CXCL11 and the platelet-derived chemokines CXCL4 and CXCL4L1. CXCL10 have been found to be implicated in several diseases, from solid and hematopoietic tumors to inflammatory or neurodegenerative disorders (Van Raemdonck et al., 2015).

 

CXCL10 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

Antonelli, A., Ferrari, S.M., Giuggioli, D., Ferrannini, E., Ferri, C., and Fallahi, P. (2014). Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272–280.

Van Raemdonck, K., Van den Steen, P.E., Liekens, S., Van Damme, J., and Struyf, S. (2015). CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev. 26, 311–327.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (2 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (8 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner